Mario Araya

@CokeHevia @FernandoAgustin Coke: ve el parido la U vs calera cuando se salva . Mira como marcan al final . Todo Esto toca lo deportivo fuertemente

Les digo a los verdaderos hinchas de la U y el fútbol que estén muy atentos a hoy en Pauta de Juego. @FernandoAgustin me escribe recién un whatsapp “Estoy dispuesto a soltar algunos datos que mantengo bajo reserva de hace mucho tiempo...”. Los esperamos

Today @OpenAI introduced ChatGPT for Clinicians, provided free for credentialed HCPs, and HealthBench Professional for benchmarking LLM medical task performance (Figure) openai.com/index/making-c… cdn.openai.com/dd128428-0184-…

@Juansextacuenta Respeto! Partidazo

Minuto 43 y Eugenio Mena ya está caminando la cancha ctm ajajajajja ex jugador

Finally, a sham-controlled CTO PCI trial—and it delivers. ORBITA-CTO: small (n=50), but rigor where it matters—blinding, placebo control, symptom-level data. CTO PCI improves angina beyond placebo, with a clear reduction in episodes and more angina-free days. Not prognosis, not hard endpoints, but real symptom benefit—properly measured. #acc26 jacc.org/doi/10.1016/j.…

Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION–STEMI trial academic.oup.com/eurheartj/arti…

Optimization of Distal Radial Access Into Clinical Routine Practice Through Ultrasound Guidance: A Review and Technical Guide imrpress.com/journal/RCM/27…

#Delirium is not “just confusion”, it is a major prognostic event in CV medicine. In our State-of-the-Art Review in #EHJ, we synthesize current evidence on mechanisms, prevention, and management across the CV continuum. 🧠🫀 acortar.link/PfFZLf @CekajEndrit et al👏👏

Clopidogrel outperformed aspirin in preventing cardiovascular events in patients with coronary artery disease (CAD), showing superior efficacy across both genders, in PANTHER-2 trial. ahajrnls.org/4tLXHTo

🧵 1/ First ever AHA/ACC/multi-society guidelines re: diagnosis & management of acute PE released today! 2 year effort with 38 authors from 10 specialties. Link attached & summary in this thread: jacc.org/doi/10.1016/j.…

The SCAPIS study published in JAMA ~25,000 🇸🇪 participants, ~8 years follow-up. Adding coronary CT angiography #CCTA plaque information improved event prediction beyond clinical risk and calcium score. This is the first study showing the added value of CCTA on top of the calcium score for risk prediction. 🎯 What to look for: lipidic soft (non-calcified) plaque. 👀 Practical takeaway: Consider a CT angiography for risk stratification on top of the calcium score. Link: jamanetwork.com/journals/jama/… 🎥 Posting my avatar summarizing the study.

With 561 references, this article—published in Nature Reviews Cardiology—is among the most comprehensive reviews of the pathophysiology, biomarkers, and therapeutic strategies addressing residual risk in coronary artery disease. Read more at bit.ly/4q3Fain

@JoaoLCavalcante Congrats!

🚨 Exciting Opportunity Alert! 🚨 Driven to master cutting-edge CV Imaging at the highest level? Minneapolis Heart Institute welcomes early interest for its 2027 Advanced Cardiovascular Imaging Fellowship (CT/MR). High quality and volume with many KOLs! allinahealth.org/for-medical-pr…

Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure. Read the results of the OPTION–STEMI trial in #EHJ 👉 ow.ly/MiAx50XTiiv @RoccoMontone @ehj_ed #heartfailure

STEMI and cardiogenic shock. A time course analysis of the use of microaxial flow pump (mAFP) and clinical outcomes from the DanGer Shock trial @CardResearchOUH @cardiac_group @RigsHeart ahajrnls.org/4jIuoN0

The risk of high lipoprotein A [Lp(a)] in nearly 28,000 healthy women followed for 30 years. Fortunately, after waiting for decades, we will have drugs vs Lp(a) soon to reduce this risk jamanetwork.com/journals/jamac…

Plaque rupture with thrombosis drives ACS, and thin-cap fibroatheroma is the archetypal high-risk plaque. There are consistent features of vulnerability across imaging modalities (large plaque burden, small MLA, TCFA, high LCBI, positive remodelling, etc.), with risk increasing when multiple features coexist. Yet absolute event rates remain low, consistent with pathology data showing most plaque ruptures are clinically silent. So should we prophylactically stent high-risk plaques? According to this Viewpoint, completed trials (PROSPECT ABSORB, PREVENT) suggest no durable reduction in death or MI versus optimal medical therapy—benefits are limited to fewer revascularisations, at the cost of many unnecessary PCIs. With modern medical therapy, a wait-and-see strategy appears safe, avoiding most interventions without adverse consequences. For now, data favor surveillance and aggressive medical therapy over preventive PCI. READ THE VIEWPOINT: eurointervention.pcronline.com/article/high-r…

Bicuspid is no longer a niche. In this SOTA, @didier_tchetche et al walk through TAVI in BAV: phenotypes, CT sizing (BAVARD, circle, CASPER), procedural tricks, long-term concerns and the need for TAVI vs SAVR RCTs. Don't miss it 👉eurointervention.pcronline.com/article/transc… #TAVI #cardiotwitter #CardioX #CardioEd @YWillemen @Vinscesario

We should read this, then read it again, then use the info in our shared decision making conversation

@mmamas1973 Important data . Congratulation @mmamas1973 and all the team

The natural history of patients with medically managed CCS is not as benign as we think. Our analysis of reconstructed individual patient's data from 29 trials and 53,000 pts shows AMI rates of 12.5% at 5 years and 8.6% mortality rate. Outcomes will be much worse in non RCT real-world populations where risk factor control less optimal and multimorbidity more prevalent. work led by @Nicholaswschew and team ➡️ link.springer.com/article/10.100…